Ocera Therapeutics fka OCRX

[ice1234]

Ocera Therapeutics Inc (OCRX) Upgraded to Buy at Zacks Investment Research
March 24th, 2017 - 0 comments - Filed Under - by Jeff Wilder

inShare
Ocera Therapeutics Inc logoZacks Investment Research upgraded shares of Ocera Therapeutics Inc (NASDAQ:OCRX) from a hold rating to a buy rating in a report issued on Thursday. The firm currently has $1.50 price objective on the biopharmaceutical company’s stock.

According to Zacks, “Ocera Therapeutics, Inc. is a biopharmaceutical company. It focused on the development and commercialization of proprietary compounds to treat acute and chronic orphan liver diseases. Ocera Therapeutics, Inc., formerly known as Tranzyme, Inc., is based in San Diego, California. “

Several other equities research analysts have also recently weighed in on the stock. Aegis restated a buy rating and issued a $3.00 price objective on shares of Ocera Therapeutics in a research report on Saturday, March 11th. Stifel Nicolaus cut shares of Ocera Therapeutics from a buy rating to a hold rating and set a $1.00 price objective for the company. in a research report on Monday, January 30th. HC Wainwright restated a buy rating and issued a $4.00 price objective on shares of Ocera Therapeutics in a research report on Friday, March 10th. Finally, JMP Securities cut shares of Ocera Therapeutics from an outperform rating to a market perform rating in a research report on Tuesday, January 31st. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The stock currently has a consensus rating of Buy and a consensus target price of $3.90.

Analyst Recommendations for Ocera Therapeutics (NASDAQ:OCRX)



Shares of Ocera Therapeutics (NASDAQ:OCRX) traded up 4.8080% during midday trading on Thursday, hitting $1.3101. 593,486 shares of the company traded hands. The stock’s 50-day moving average is $0.89 and its 200 day moving average is $1.92. Ocera Therapeutics has a 12-month low of $0.52 and a 12-month high of $3.27. The stock’s market capitalization is $30.92 million.

A number of large investors have recently bought and sold shares of the stock. Great Point Partners LLC bought a new stake in Ocera Therapeutics during the third quarter valued at $5,184,000. Interwest Venture Management Co. bought a new stake in Ocera Therapeutics during the fourth quarter valued at $2,621,000. VHCP Management II LLC boosted its stake in Ocera Therapeutics by 14.8% in the third quarter. VHCP Management II LLC now owns 1,088,372 shares of the biopharmaceutical company’s stock valued at $2,873,000 after buying an additional 140,000 shares during the last quarter. VHCP Management LLC boosted its stake in Ocera Therapeutics by 7.5% in the third quarter. VHCP Management LLC now owns 856,550 shares of the biopharmaceutical company’s stock valued at $2,261,000 after buying an additional 60,000 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its stake in Ocera Therapeutics by 17.9% in the fourth quarter. Renaissance Technologies LLC now owns 219,100 shares of the biopharmaceutical company’s stock valued at $460,000 after buying an additional 33,300 shares during the last quarter. Hedge funds and other institutional investors own 35.00% of the company’s stock.

About Ocera Therapeutics

Ocera Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on acute and chronic orphan liver diseases. The Company is focused on the development and commercialization of its clinical candidate, OCR-002, for the treatment of hepatic encephalopathy (HE). OCR-002 is a molecule, ornithine phenylacetate, which functions as an ammonia scavenger

http://www.dailypolitical.com/2017/03/24/ocera-therapeutics-inc-ocrx-upgraded-to-buy-at-zacks-investment-research.html